Angelo Antonini presents real-world data from the PRISM study, highlighting the prevalence of impulse control disorders in patients with Parkinson’s disease and their association with dopamine agonists (5:34).
Funding for independent interviews at EAN 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.